Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …

Purpose The general outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first
remission is important information for patients and for planning post-treatment follow-up. The …

Diffuse large B‐cell lymphoma (DLBCL) is the commonest type of lymphoid tumour world‐
wide. This category was included both in the REAL and WHO Classification aiming to lump …

Diffuse large B-cell lymphoma (DLBCL) as defined by the World Health Organization (WHO)
classification is clinically, morphologically and genetically a heterogeneous group of …

Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …

Abstract Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin,
vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma …

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin
lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up …

Background The prognosis of young patients with diffuse large B-cell lymphoma at high risk
(age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated with R-CHOP …

Outcome in diffuse large B-cell lymphoma (DLBCL) has improved over the last decade and
will likely improve further with the introduction of novel agents. At the present time, clinical …